|Bid||115.00 x 800|
|Ask||150.00 x 1000|
|Day's range||134.11 - 139.90|
|52-week range||79.88 - 195.97|
|Beta (3Y monthly)||3.14|
|PE ratio (TTM)||N/A|
|Earnings date||30 Jul 2018 - 3 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||201.38|
The longest government shutdown in U.S. history could logjam drug approvals and clinical tests at the Food and Drug Administration, analysts said Tuesday. Several biotech stocks are at risk.
Two new deals to start the year and positive trial presentations at the J.P. Morgan Health Care conference have breathed new life into some of last year's biggest stock losers.
These companies arguably stole the show at J.P. Morgan's high-profile healthcare conference this year.
It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.
The tiny pharma company reported promising results in a study for its lead drug candidate, eliciting comparisons to a reputable high-flying peer.
Jim Cramer says leading drugmakers are innovating more than ever before and many of their stocks are worth owning.
Three Healthcare Stocks Rallying Over 10% Today ## Three healthcare stocks The broader market is trading in the green territory today but largely on a mixed note compared to the volatility in the previous couple of sessions. At 11:40 AM ET, the S&P 500 Index (SPY), NASDAQ Composite Index (QQQ), and Dow Jones Industrial Average were trading with 0.8%, 1.1%, and 0.6% gains. However, some healthcare stocks (XLV)(VHT)(IBB) were making huge moves today. Let’s take a look. ## Loxo Oncology Today before the market opened, the American pharmaceutical giant Eli Lilly and Company (LLY) announced the acquisition of Loxo Oncology (LOXO). According to the agreement between the two companies, Eli Lilly will acquire Loxo for $235.00 per share in cash, which translates into approximately $8.0 billion. After the news came out, Loxo stock surged nearly 66.0% to $232.12. ## Sage Therapeutics The biopharmaceutical firm Sage Therapeutics (SAGE) revealed positive results of the Phase 3 ROBIN Study today. The outcome of the study suggested a “significant improvement” in women with postpartum depression (or PPD) who were treated with its SAGE-217 drug for two weeks. This news boosted investors’ confidence, and SAGE stock surged 62.1% to a day high of $158.09. ## Exact Sciences The molecular diagnostics firm Exact Sciences (EXAS) said today that it expects its fourth quarter of 2018 revenue between $142.5 million and $143.5 million, which reflected about a 64% rise in its revenue from the fourth quarter of the previous year. In a press release, the company said that it “completed approximately 292,000 Cologuard tests during the fourth quarter of 2018,” up about 66% year-over-year. Plus, Exact Sciences noted, “Nearly 15,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2018.” These positive developments drove EXAS stock to rally today to post a day high of $72.78, up 11.0% from its previous session’s closing price. Note that in 2018, LOXO, LLY, and EXAS rose 66.4%, 37.0%, and 20.1%, respectively, while SAGE fell 41.8%.
Sage Therapeutics: Results from the Phase 3 ROBIN Trial ## Sage Therapeutics’ ROBIN trial On January 7, Sage Therapeutics presented the results of the Phase 3 ROBIN trial. The trial evaluated the safety, efficacy, and other pharmacological parameters of SAGE-217 in females with severe postpartum depression. In the ROBIN trial, SAGE-217 met the clinical trial’s primary and secondary endpoints. In the trial, patients receiving SAFE-217 demonstrated a statistically significant improvement of 17.8 points in the HAMD-17 (Hamilton Rating Scale for Depression) score. Patients receiving a placebo had a score of 13.6 points. In the trial, 45% of the patients receiving SAGE-217 achieved remission—compared to 23% of the patients receiving a placebo. To learn more about the clinical trial results, read Sage Therapeutics’ press release. The success in the clinical trial will help Sage Therapeutics with supportive data for submitting a New Drug Application to different regulatory authorities across the world to commercialize the drug. ## Stock performance On January 4, Sage Therapeutics’ stock price closed at $97.51, which represents ~9.16% growth from its previous close of $89.33 on January 3. On December 31, Sage Therapeutics’ stock price grew ~7.64% to $95.76 from its previous close of $88.99 on December 28. On January 4, the company’s stock price closed at $97.51, which is ~51% below its 52-week high of $195.97 on January 31, 2018. Sage Therapeutics hit its 52-week low of $79.88 on December 24. ## Analysts’ recommendations Among the 17 analysts tracking Sage Therapeutics in January, eight recommended a “strong buy,” eight recommended a “buy,” and one recommended a “sell.” On January 7, Sage Therapeutics had a consensus 12-month target price of $200.13, which is an ~105.24% return on investment over the next 12 months.
NEW YORK, Jan. 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Sage Therapeutics, Inc. (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Chief Executive Officer, Jeff Jonas, M.D., will discuss the Company’s progress as a leading, multi-franchise CNS company in a corporate presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. “We’ve made significant progress over the last eight years and our innovative approach to discovery and development has resulted in five consecutive positive trials in mood disorders,” said Jeff Jonas, M.D., chief executive officer at Sage. As we prepare to advance our lead product candidate from development to planned commercialization, we believe we are delivering on that promise.
Sage Therapeutics (SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported top-line results from the Phase 3 ROBIN Study. This study evaluated the effect of SAGE-217 30 mg on depressive symptoms in women with postpartum depression (PPD). After two weeks of outpatient treatment, patients treated with SAGE-217 had a statistically significant improvement of 17.8 points in the Hamilton Rating Scale for Depression (HAMD-17) score, compared to 13.6 for placebo (primary endpoint, p=0.0029), with statistically significant reductions in HAMD-17 compared to placebo maintained through the end of the four-week follow-up.
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 15,000 shares of its common stock to five new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Sage Therapeutics (SAGE) needs investors to pay close attention to the stock based on moves in the options market lately.
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the J.P.
Sarepta Therapeutics, Sage Therapeutics and Loxo Oncology are the most likely takeover candidates among biotech stocks in 2019, according to a survey from RBC Capital Markets analysts.
In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively. The company’s revenues are expected to increase to $156.84 million in fiscal 2020. Biogen (BIIB), BioMarin Pharmaceutical (BMRN), and Sarepta Therapeutics (SRPT) are expected to have revenues of $13.31 billion, $1.52 billion, and $301.13 million, respectively, in fiscal 2018.
In the third quarter, Sage Therapeutics’ (SAGE) net interest income was $5.82 million—compared to $677,000 during the same period in 2017.
Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical company that focuses on developing treatments for central nervous system disorders. In this series, we’ll explore Sage Therapeutics’ financials, valuation, and analysts’ views on the stock.
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on December 3, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 156,100 shares of its common stock to 93 new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.